Endocrine treatment in breast cancer: Cure, resistance and beyond

Konstantinos Tryfonidis, Dimitrios Zardavas, Benita S Katzenellenbogen, Martine Piccart

Research output: Contribution to journalReview article

Abstract

Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments. Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development. Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted. However, predictive biomarkers for accurate ‘navigation’ across the different treatment options are urgently needed. In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.

Original languageEnglish (US)
Pages (from-to)68-81
Number of pages14
JournalCancer Treatment Reviews
Volume50
DOIs
StatePublished - Nov 1 2016

Fingerprint

Tumor Microenvironment
Biomarkers
Hormones
Breast Neoplasms
Recurrence
Neoplasms
Therapeutics

Keywords

  • Endocrine treatment
  • Molecular mechanisms
  • New agents
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Endocrine treatment in breast cancer : Cure, resistance and beyond. / Tryfonidis, Konstantinos; Zardavas, Dimitrios; Katzenellenbogen, Benita S; Piccart, Martine.

In: Cancer Treatment Reviews, Vol. 50, 01.11.2016, p. 68-81.

Research output: Contribution to journalReview article

Tryfonidis, Konstantinos ; Zardavas, Dimitrios ; Katzenellenbogen, Benita S ; Piccart, Martine. / Endocrine treatment in breast cancer : Cure, resistance and beyond. In: Cancer Treatment Reviews. 2016 ; Vol. 50. pp. 68-81.
@article{61261b98aae04fe2a9e1aab7ea2a1574,
title = "Endocrine treatment in breast cancer: Cure, resistance and beyond",
abstract = "Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70{\%}), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments. Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development. Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted. However, predictive biomarkers for accurate ‘navigation’ across the different treatment options are urgently needed. In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.",
keywords = "Endocrine treatment, Molecular mechanisms, New agents, Resistance",
author = "Konstantinos Tryfonidis and Dimitrios Zardavas and Katzenellenbogen, {Benita S} and Martine Piccart",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.ctrv.2016.08.008",
language = "English (US)",
volume = "50",
pages = "68--81",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Endocrine treatment in breast cancer

T2 - Cure, resistance and beyond

AU - Tryfonidis, Konstantinos

AU - Zardavas, Dimitrios

AU - Katzenellenbogen, Benita S

AU - Piccart, Martine

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments. Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development. Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted. However, predictive biomarkers for accurate ‘navigation’ across the different treatment options are urgently needed. In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.

AB - Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments. Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development. Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted. However, predictive biomarkers for accurate ‘navigation’ across the different treatment options are urgently needed. In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.

KW - Endocrine treatment

KW - Molecular mechanisms

KW - New agents

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84988040443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988040443&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.08.008

DO - 10.1016/j.ctrv.2016.08.008

M3 - Review article

C2 - 27643748

AN - SCOPUS:84988040443

VL - 50

SP - 68

EP - 81

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -